Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease
Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study
Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation
Phase III Regorafenib Trial Meets PFS Primary Endpoint
Radium-233 Dichloride Increased Overall Survival in Phase III Trial
Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone
Nexavar Phase III Trial Fails To Meet Primary Endpoint
Alimta/Cisplatin Chemotherapy Increased Overall Survival
New Carfilzomib Combination Produces Near Remissions
Trial Data: No Benefit In Adding Perifosine to Capecitabine
Blinatumomab Demonstrates High Response Rate in ALL
MET Inhibitor Improved Time To Progression by 56 Percent
NCI-Approved CTEP Trials For The Month of June
Trending Stories
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
